Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy

Eiki Takimoto, Hunter C. Champion, Manxiang Li, Diego Belardi, Shuxun Ren, E. Rene Rodriguez, Djahida Bedja, Kathleen L Gabrielson, Yibin Wang, David A Kass

Research output: Contribution to journalArticle

Abstract

Sustained cardiac pressure overload induces hypertrophy and pathological remodeling, frequently leading to heart failure. Genetically engineered hyperstimulation of guanosine 3′,5′-cyclic monophosphate (cGMP) synthesis counters this response. Here, we show that blocking the intrinsic catabolism of cGMP with an oral phosphodiesterase-5A (PDE5A) inhibitor (sildenafil) suppresses chamber and myocyte hypertrophy, and improves in vivo heart function in mice exposed to chronic pressure overload induced by transverse aortic constriction. Sildenafil also reverses pre-established hypertrophy induced by pressure load while restoring chamber function to normal. cGMP catabolism by PDE5A increases in pressure-loaded hearts, leading to activation of cGMP-dependent protein kinase with inhibition of PDE5A. PDE5A inhibition deactivates multiple hypertrophy signaling pathways triggered by pressure load (the calcineurin/NFAT, phosphoinositide-3 kinase (PI3K)/Akt, and ERK1/2 signaling pathways). But it does not suppress hypertrophy induced by overexpression of calcineurin in vitro or Akt in vivo, suggesting upstream targeting of these pathways. PDE5A inhibition may provide a new treatment strategy for cardiac hypertrophy and remodeling.

Original languageEnglish (US)
Pages (from-to)214-222
Number of pages9
JournalNature Medicine
Volume11
Issue number2
DOIs
StatePublished - Feb 2005

Fingerprint

Type 5 Cyclic Nucleotide Phosphodiesterases
Cyclic GMP
Cardiomegaly
Hypertrophy
Pressure
Calcineurin
Cyclic GMP-Dependent Protein Kinases
1-Phosphatidylinositol 4-Kinase
Phosphodiesterase Inhibitors
MAP Kinase Signaling System
Guanosine
Phosphatidylinositols
Constriction
Muscle Cells
Phosphotransferases
Heart Failure
Chemical activation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Takimoto, E., Champion, H. C., Li, M., Belardi, D., Ren, S., Rodriguez, E. R., ... Kass, D. A. (2005). Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nature Medicine, 11(2), 214-222. https://doi.org/10.1038/nm1175

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. / Takimoto, Eiki; Champion, Hunter C.; Li, Manxiang; Belardi, Diego; Ren, Shuxun; Rodriguez, E. Rene; Bedja, Djahida; Gabrielson, Kathleen L; Wang, Yibin; Kass, David A.

In: Nature Medicine, Vol. 11, No. 2, 02.2005, p. 214-222.

Research output: Contribution to journalArticle

Takimoto, E, Champion, HC, Li, M, Belardi, D, Ren, S, Rodriguez, ER, Bedja, D, Gabrielson, KL, Wang, Y & Kass, DA 2005, 'Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy', Nature Medicine, vol. 11, no. 2, pp. 214-222. https://doi.org/10.1038/nm1175
Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nature Medicine. 2005 Feb;11(2):214-222. https://doi.org/10.1038/nm1175
Takimoto, Eiki ; Champion, Hunter C. ; Li, Manxiang ; Belardi, Diego ; Ren, Shuxun ; Rodriguez, E. Rene ; Bedja, Djahida ; Gabrielson, Kathleen L ; Wang, Yibin ; Kass, David A. / Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. In: Nature Medicine. 2005 ; Vol. 11, No. 2. pp. 214-222.
@article{b5176d70d663408c9475eb323fefe4e9,
title = "Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy",
abstract = "Sustained cardiac pressure overload induces hypertrophy and pathological remodeling, frequently leading to heart failure. Genetically engineered hyperstimulation of guanosine 3′,5′-cyclic monophosphate (cGMP) synthesis counters this response. Here, we show that blocking the intrinsic catabolism of cGMP with an oral phosphodiesterase-5A (PDE5A) inhibitor (sildenafil) suppresses chamber and myocyte hypertrophy, and improves in vivo heart function in mice exposed to chronic pressure overload induced by transverse aortic constriction. Sildenafil also reverses pre-established hypertrophy induced by pressure load while restoring chamber function to normal. cGMP catabolism by PDE5A increases in pressure-loaded hearts, leading to activation of cGMP-dependent protein kinase with inhibition of PDE5A. PDE5A inhibition deactivates multiple hypertrophy signaling pathways triggered by pressure load (the calcineurin/NFAT, phosphoinositide-3 kinase (PI3K)/Akt, and ERK1/2 signaling pathways). But it does not suppress hypertrophy induced by overexpression of calcineurin in vitro or Akt in vivo, suggesting upstream targeting of these pathways. PDE5A inhibition may provide a new treatment strategy for cardiac hypertrophy and remodeling.",
author = "Eiki Takimoto and Champion, {Hunter C.} and Manxiang Li and Diego Belardi and Shuxun Ren and Rodriguez, {E. Rene} and Djahida Bedja and Gabrielson, {Kathleen L} and Yibin Wang and Kass, {David A}",
year = "2005",
month = "2",
doi = "10.1038/nm1175",
language = "English (US)",
volume = "11",
pages = "214--222",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy

AU - Takimoto, Eiki

AU - Champion, Hunter C.

AU - Li, Manxiang

AU - Belardi, Diego

AU - Ren, Shuxun

AU - Rodriguez, E. Rene

AU - Bedja, Djahida

AU - Gabrielson, Kathleen L

AU - Wang, Yibin

AU - Kass, David A

PY - 2005/2

Y1 - 2005/2

N2 - Sustained cardiac pressure overload induces hypertrophy and pathological remodeling, frequently leading to heart failure. Genetically engineered hyperstimulation of guanosine 3′,5′-cyclic monophosphate (cGMP) synthesis counters this response. Here, we show that blocking the intrinsic catabolism of cGMP with an oral phosphodiesterase-5A (PDE5A) inhibitor (sildenafil) suppresses chamber and myocyte hypertrophy, and improves in vivo heart function in mice exposed to chronic pressure overload induced by transverse aortic constriction. Sildenafil also reverses pre-established hypertrophy induced by pressure load while restoring chamber function to normal. cGMP catabolism by PDE5A increases in pressure-loaded hearts, leading to activation of cGMP-dependent protein kinase with inhibition of PDE5A. PDE5A inhibition deactivates multiple hypertrophy signaling pathways triggered by pressure load (the calcineurin/NFAT, phosphoinositide-3 kinase (PI3K)/Akt, and ERK1/2 signaling pathways). But it does not suppress hypertrophy induced by overexpression of calcineurin in vitro or Akt in vivo, suggesting upstream targeting of these pathways. PDE5A inhibition may provide a new treatment strategy for cardiac hypertrophy and remodeling.

AB - Sustained cardiac pressure overload induces hypertrophy and pathological remodeling, frequently leading to heart failure. Genetically engineered hyperstimulation of guanosine 3′,5′-cyclic monophosphate (cGMP) synthesis counters this response. Here, we show that blocking the intrinsic catabolism of cGMP with an oral phosphodiesterase-5A (PDE5A) inhibitor (sildenafil) suppresses chamber and myocyte hypertrophy, and improves in vivo heart function in mice exposed to chronic pressure overload induced by transverse aortic constriction. Sildenafil also reverses pre-established hypertrophy induced by pressure load while restoring chamber function to normal. cGMP catabolism by PDE5A increases in pressure-loaded hearts, leading to activation of cGMP-dependent protein kinase with inhibition of PDE5A. PDE5A inhibition deactivates multiple hypertrophy signaling pathways triggered by pressure load (the calcineurin/NFAT, phosphoinositide-3 kinase (PI3K)/Akt, and ERK1/2 signaling pathways). But it does not suppress hypertrophy induced by overexpression of calcineurin in vitro or Akt in vivo, suggesting upstream targeting of these pathways. PDE5A inhibition may provide a new treatment strategy for cardiac hypertrophy and remodeling.

UR - http://www.scopus.com/inward/record.url?scp=20044363270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044363270&partnerID=8YFLogxK

U2 - 10.1038/nm1175

DO - 10.1038/nm1175

M3 - Article

C2 - 15665834

AN - SCOPUS:20044363270

VL - 11

SP - 214

EP - 222

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 2

ER -